Non–Small Cell Lung Cancer, Version 6.2015

Lymph Node Assessment and Impact on Survival in Video-Assisted Thoracoscopic Lobectomy or Segmentectomy

“…There is no accepted recommendation for RNs; however, the 2013 National Comprehensive Cancer Network guidelines recommend sampling at least 3 mediastinal lymph node stations at the time of pulmonary resection [20]. In a secondary analysis of the American College of Surgeons Oncology Group Z0030 trial (where w 1,023 stage I patients were randomized to mediastinal lymph node sampling versus mediastinal lymph node dissection), the median RNs were similar between VATS and open (15 [range, 5 to 48]) vs 19 [range, 2 to 83], p ¼ 0.147) [21].…”

Prognostic and predictive value of the novel classification of lung adenocarcinoma in patients with stage IB

“…However, the benefit of adjuvant chemotherapy (ACT) among stage IB patients remains controversial. The National Comprehensive Cancer Network (NCCN) guideline suggested patients in stage IB should consider adjuvant chemotherapy with high-risk factors including tumor size greater than 4 cm, visceral pleura invasion, lymphovascular invasion, poorly differentiated, wedge resection or incomplete lymph node sampling (Nx) (Ettinger et al 2015). However, this recommendation is category 2B, lacking for high-level evidence and uniform NCCN consensus.…”

Identification of Commonly Dysregulated Genes in Non-small-cell Lung Cancer by Integrated Analysis of Microarray Data and qRT-PCR Validation

“…The predicted 5-year survival rate of NSCLC patients is 15.9 %, and little improvement has been reached during the past few decades [3]. Due to the poor clinical outcome, substantial researches focus on uncovering the molecular mechanism of NSCLC, providing insights into potential therapeutic targets.…”